RMTG's Cellgenic Launches in Peru Expanding into Latin America

Regenerative Medical Technology Group’s (RMTG) biologics and product-commercialization division, Cellgenic, has launched commercial activities in Peru, marking a significant step in the company’s expansion across Latin America. This move follows similar initiatives in Brazil and Colombia, part of RMTG’s ongoing growth strategy in the region.

On September 1, 2026, RMTG announced the establishment of local commercial arrangements in Peru, including exclusive representation in permitted channels. The company aims to develop relationships with physicians and medical providers in Peru, consistent with its approach in other Latin American markets, all subject to Peruvian regulatory requirements and the terms of local agreements.

“Peru’s physician community has shown a growing interest in regenerative medicine, making it a natural fit for Cellgenic’s expansion,” said David Christensen, CEO and President of RMTG. “Establishing a local presence is a key step in building out our Latin American network.”

Christensen emphasized that the Peru market entry is part of a deliberate, market-by-market strategy rather than a single revenue event. The company has not determined if the Peru arrangements will be material to its financial results, and there is no assurance of generating meaningful or recurring revenue.

RMTG operates through its wholly owned subsidiary, Global Stem Cells Group, and has a presence in over 30 countries. Cellgenic, a division of Global Stem Cells Group, develops and distributes advanced cellular and biologic products to physicians and clinics in permitted international markets.

While the company is not making therapeutic claims in this announcement, it notes that its products are offered to licensed physicians and clinics only in markets where such distribution is permitted under local law. These products are not approved by the U.S. Food and Drug Administration for commercial use in the United States.

The Peru market entry is one of three coordinated initiatives in RMTG’s current Latin American growth phase, alongside Brazil and Colombia. Further activities in Brazil and Colombia remain subject to local requirements and are not considered completed by this release.

“Each new market we enter broadens the base of physicians and clinics that Cellgenic can support, contributing to a regional commercial network designed to build long-term product relationships,” Christensen added.

However, RMTG remains cautious, acknowledging that the Peru arrangements may not result in material revenue or recurring demand. The company’s growth strategy is subject to various risks, including regulatory developments, market acceptance, operational execution, and competitive conditions.

“Regulatory and market conditions can significantly impact our operations,” Christensen noted. “We are committed to navigating these challenges and executing our strategy with precision.”

For additional information about RMTG’s business, operations, and risks, interested parties can review the company’s filings with the Securities and Exchange Commission.

“While the future is uncertain, RMTG remains steadfast in its commitment to advancing regenerative medicine and supporting the needs of physicians and patients across Latin America,” Christensen concluded.